Indications: SPRAVATO® (esketamine) CIII Nasal Spray is indicated, in conjunction with an oral antidepressant, for the treatment of: Treatment-resistant depression (TRD) in adults. Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. Limitations of Use: The effectiveness of SPRAVATO® in preventing suicide or in
Indications: SPRAVATO® (esketamine) CIII Nasal Spray is indicated, in conjunction with an oral antidepressant, for the treatment of: Treatment-resistant depression
Copyright © 2024 West Cayuga Medicine. All rights reserved.